Targeting with FLT3 Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

December 8, 2017

Georgia World Congress Center, Atlanta, GA

12:30 - 1:30 Light Buffet
Rooms B405-B406

1:30 - 4:30 Symposium
Rooms B401-B402

Given the rapid development of FLT3 inhibitors in AML treatment paradigms, healthcare professionals are in need of an educational activity that will enable safe and efficacious integration of these agents in clinical practice. The proposed program will aid attendees in staying abreast of the most recent advances in the field and will provide expert guidance and recommendations to facilitate integration of crucial developments in the treatment and management of AML.